DCPH

Deciphera Pharmaceuticals (DCPH) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov^[4], including 3 Phase 3^[1], 4 Phase 2^[2], 4 Phase 1^[3].

Trial NCT03673501^[5] evaluates Ripretinib in Gastrointestinal Stromal Tumors with a target enrollment of 453 participants. Trial NCT05734105^[6] evaluates Ripretinib in GIST with a target enrollment of 54 participants. Trial NCT05059262^[7] evaluates Vimseltinib in Tenosynovial Giant Cell Tumor with a target enrollment of 123 participants.

No Form 4 insider filings for DCPH were recorded at the SEC in the past 30 days^[8].